secwatch.observer — SEC 8-K summary
======================================

Issuer:     Outset Medical, Inc. (OM)
CIK:        0001484612
Form:       8-K
Filed at:   2026-01-12T23:59:59+00:00
Accession:  0001193125-26-009865
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Outset Medical prelim Q4 rev $28.9M; FY2025 rev $119.5M (+5% YoY); cash $173M; appoints Prange
--------------------------------------------------------------------------------

- Q4 2025 revenue ~$28.9M; full-year 2025 revenue $119.5M, up 5% from $113.7M in 2024.
- Year-end cash (incl. restricted cash & short-term investments) $173M; net cash used in ops <$50M vs $116M in 2024.
- Over 1,000 sites insource dialysis with Outset; ~1M treatments/year; cumulative >3M treatments on Tablo.
- Andrea Saia resigned from board effective Jan 9, 2026; Karen Prange appointed to board and Compensation Committee.
- Prange brings med device exec experience (Henry Schein, Boston Scientific, Johnson & Johnson).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1484612/000119312526009865/0001193125-26-009865-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1484612/000119312526009865/om-20260107.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-009865

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer